GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline, GlaxoSmithKline (GSK) has announced a deal worth up to $2 billion to acquire efimosfermin, a promising treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), from Boston Pharmaceuticals. The British pharma giant is paying $1.2 billion upfront, with an additional $800 million tied to future development and sales milestones. This acquisition is one of GSK’s largest bets…